Chemical compound extends survival by months, in mice
Pancreatic cancer is especially challenging to treat – only eight percent of patients are still alive five years after diagnosis. Chemotherapy and radiation therapy are of limited benefit, and even immunotherapy – which revolutionized treatment for other kinds of cancer by activating the body’s immune system to attack cancer cells – has been largely ineffective because pancreatic tumors have ways to dampen the immune assault.
Now, researchers at Washington University School of Medicine in St. Louis and Rush University in Chicago have found a chemical compound that promotes a vigorous immune assault against the deadly cancer. Alone, the compound reduces pancreatic tumor growth and metastases in mice. But when combined with immunotherapy, the compound significantly shrank tumors and dramatically improved survival in the animals.
The findings, published July 3 in Science Translational Medicine, suggest that the immune-boosting compound could potentially make resistant pancreatic cancers susceptible to immunotherapy and improve treatment options for people with the devastating disease.
“Pancreatic cancer is a highly lethal disease, and we are in desperate need of new therapeutic approaches,” said co-senior author David DeNardo, PhD, an associate professor of medicine and of pathology and immunology at Washington University School of Medicine. “In animal studies, this small molecule led to very marked improvements and was even curative in some cases. We are hopeful that this approach could help pancreatic cancer patients.”
On paper, immunotherapies for pancreatic cancer seem like a good idea. The technique works by releasing a brake on specialized immune cells called T cells so they can attack the cancer. In the past, researchers working in the lab found they could release the brake and prod T cells into killing pancreatic cancer cells. But when doctors tried to treat people with pancreatic cancer using immunotherapies, fewer than five percent of patients improved.
This failure of immunotherapy in pancreatic cancer has puzzled scientists. But T cells aren’t the only player in the immune assault on cancer. Myeloid cells, another kind of immune cell found in and around tumors, can either tamp down or ramp up the immune response. They tilt the playing field by releasing immune molecules that affect how many T cells are recruited to the tumor, and whether the T cells show up at the tumors activated and ready to kill, or suppressed and inclined to ignore the tumor cells. In pancreatic tumors, myeloid cells typically suppress other immune cells, undermining the effects of immunotherapy.
DeNardo, co-senior author Vineet Gupta, PhD, of Rush University, and colleagues realized that releasing the brake on T cells might not be enough to treat pancreatic cancer. Unleashing the power of immunotherapy might require also shifting the balance of myeloid cells toward those that activate T cells to attack.
The researchers identified a compound, called ADH-503, that interferes with the migration of myeloid cells. Normally, pancreatic tumors are teeming with myeloid cells that suppress the immune response. When the researchers gave the compound to mice with pancreatic cancer, the number of myeloid cells in and near the tumors dropped, and the remaining myeloid cells were of the kind that promoted, rather than suppressed, immune responses. This environment translated into greater numbers of cancer-killing T cells in the tumor, significantly slower tumor growth and longer survival.
Then, the researchers – including first author Roheena Panni, MD, resident in general surgery at Washington University and Barnes-Jewish Hospital, and co-author William Hawkins, MD, the Neidorff Family and Robert C. Packman Professor of Surgery at Washington University School of Medicine – investigated whether creating this same environment could make pancreatic tumors susceptible to standard immunotherapy. First, they treated mice with a so-called PD-1 inhibitor, a standard immunotherapy used to treat other kinds of cancer. Unsurprisingly, they saw no effect. But when the researchers gave the mice the immunotherapy in conjunction with ADH-503, the tumors shrank and the mice survived significantly longer. In some experiments, all the tumors disappeared within a month of treatment, and all the mice survived for four months, when the researchers stopped monitoring them. In comparison, all the untreated mice died within six weeks.
Gupta noted that while pancreatic cancer is the third leading cause of cancer-related death in the United States, only about three percent of clinical trials for cancer immunotherapies target pancreatic cancer.
“Unlocking the promise of immunotherapies for pancreatic cancer requires a new approach,” Gupta said. “We believe these data demonstrate that targeting myeloid cells can help overcome resistance to immunotherapies.”
The strategy of boosting antitumor immune activity by shifting the balance of myeloid cells improved the effectiveness of other pancreatic cancer therapies as well, the researchers said. Mice treated with chemotherapy or radiation therapy both fared significantly better when ADH-503 was added to the regimen.
“You can’t make a one-to-one translation between animal studies and people, but this is very encouraging,” DeNardo said. “More study is needed to understand if the compound is safe and effective in people, which is why Gossamer Bio, Inc., is starting phase I safety studies in people later this year at Washington University and other sites.”
Learn more: Immune-boosting compound makes immunotherapy effective against pancreatic cancer
The Latest on: Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pancreatic cancer
- Holiday Market and Food Tasting raises funds for pancreatic cancer researchon March 31, 2023 at 4:45 am
A cancer survivor has paired up with a local restaurant to raise funds for URMC Wilmot Cancer Institute research by hosting a Holiday Market and Food Tasting fundraiser in Fairport on Sunday. Angela ...
- ‘Horrible smell’ could help doctors diagnose pancreatic cancer at an early stageon March 30, 2023 at 6:13 am
Some of the most telling signs show up in a person's stool, because when a pancreatic duct becomes blocked by a tumour there are insufficient pancreatic juices in the intestines. This can allow ...
- Air Force Academy, Harvard part of Marsh’s pancreatic cancer research passionon March 29, 2023 at 12:38 pm
Madison Marsh is beyond busy. The Fort Smith native will graduate from the U.S. Air Force Academy in June. After that, she plans to attend the Harvard Kennedy School ...
- Advanced pancreatic cancer model more accurately depicts PDAC tumor progressionon March 29, 2023 at 11:33 am
Pancreatic ductal adenocarcinoma (PDAC), is highly aggressive and lethal. It is the most prevalent type of pancreatic cancer, making up 90% of cases; it also has a high rate of metastasis, with an ...
- Pancreatic Cancer Breakthrough: Discovery Suggests Possible Way To Treat Deadly Disease — And A Drug Already Exists To Do Iton March 29, 2023 at 8:53 am
The breakthrough, which targets the unique metabolic pathway used by cancer cells, could starve tumors while leaving the rest of the body unharmed.
- Transcenta's Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Canceron March 29, 2023 at 12:27 am
Orphan drugs are used for the prevention, treatment, and diagnosis of rare diseases. The ODD granted by the US FDA is applicable to drugs and biologics for rare diseases with less than 200,000 ...
- Advanced pancreatic cancer model for developing personalized therapieson March 28, 2023 at 5:00 pm
Scientists from the Terasaki Institute for Biomedical Innovation have recently designed an advanced pancreatic tumor model which more accurately depicts pancreatic ductal adenocarcinoma tumor ...
- Biomarkers show promise for identifying early risk of pancreatic canceron March 28, 2023 at 12:19 pm
A research team has identified a set of biomarkers that could help distinguish whether cysts on the pancreas are likely to develop into cancer or remain benign. A research team at Duke Health has ...
- Cracking the Code: Unlocking Pancreatic Cancer Risk Factorson March 28, 2023 at 10:17 am
After analyzing lifestyle factors and medical conditions, researchers have uncovered potential areas for prevention and early diagnosis of pancreatic cancer.
- Researchers receive NCI grant to advance new treatment approach for pancreatic canceron March 28, 2023 at 9:42 am
Genel, Ph.D., have received a grant from the National Cancer Institute to advance a new treatment approach for pancreatic cancer.
via Bing News